• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Biosckin

Biosckin

Molecular and Cell Therapies, S.A

  • Biosckin
  • Regenerative Medicine
    and Tissue Engineering
    • Cell therapies
    • Biomaterials
  • Products & Services
    • Covid-19 Products
    • Tests of Cyto and Biocompatibility
    • Cryopreservation of stem cells
    • Bonelike by Biosckin®
    • Flow cytometry
    • Growth factors from umbilical cord blood and dental pulp – CELLSECRET®
  • ID&I Nucleus
    • Projects
  • Contact us
  • English
  • Portuguese (Portugal)
Está aqui: Home / Regenerative Medicine and Tissue Engineering

Regenerative Medicine and Tissue Engineering

Tissue Engineering was originally defined by Skalak and Fox, in 1988 as ‘the application of the principles and methods of engineering and life sciences towards the fundamental understanding of structure-function relationships in normal and pathological mammalian tissues and the development of biological substitutes to restore, maintain, or improve functions’.

Later, Langer and Vacanti, in 1993, defined three main pillars of Tissue Engineering principles, the (i) isolated cells and substitutes – cellular systems and cellular products; (ii) tissue-inducing substances – bioactive molecules; and (iii) scaffolds, biomaterials and/or matrices.

Significant progress has been made in stem cells-based Regenerative Medicine, which enables researchers and clinicians to treat those diseases which cannot be cured by conventional treatments. The unlimited self-renewal and multi-lineage differentiation potential to other types of cells and their capacity to produce bioactive molecules and regenerative products, causes stem cells to be frontier in Regenerative Medicine. Researches in Regenerative Medicine have been focused on human and animal cells including embryonic as well as adult stem cells or even somatic cells.

Stem cell therapy has been developed in the last decade. Nevertheless, obstacles including unwanted side effects due to the migration of transplanted cells as well as poor cell survival have remained unresolved. In order to overcome these problems, cell therapy and cell-based therapy has been introduced using biocompatible and biodegradable biomaterials to reduce cell loss and long-term in vitro retention of stem cells. Currently in clinical trials, these biomaterials are widely used in drug and cell-delivery systems, Regenerative Medicine and Tissue Engineering in which to allow the long-term survival and controlled release.

Cell therapies
and cell-based therapies

Read more

Biomaterials

Read more

Breaking News

PrintONorgans – Direct Biomanufacturing on Organs
Biosckin distinguida como PME Líder
Biosckin celebra parceria exclusiva com laboratório pioneiro na área de genética
Biosckin – laboratório Criovida tem protocolo científico com a Universidade do Porto desde 2007
Número crescente de aplicações clínicas das células estaminais do sangue do cordão umbilical
Biosckin, 10 anos de experiência e rigor
Grande potencial terapêutico das células estaminais do tecido do cordão umbilical em doenças do sistema imunológico
Biosckin no Projecto Inovação Portugal
Utilização de células estaminais do tecido do cordão umbilical na regeneração de lesões de nervo periférico
O avanço da utilização de células estaminais autólogas na área da medicina regenerativa
Uso do sangue do cordão umbilical em crianças com paralisia cerebral
Slider

Footer

Contacts

Biosckin, Molecular and Cell Therapies, S.A.

Tecmaia – Parque de Ciência e Tecnologia da Maia
Rua Engenheiro Frederico Ulrich, 2650
4470-605 – Moreira da Maia
Portugal

Telephone: (+351) 220 915 495
(+351) 220 915 498
Fax: (+351) 229 428 206

E-Mail: info@biosckin.com

  • LinkedIn

Sitemap

  • Biosckin
  • Regenerative Medicine and Tissue Engineering
  • Products & Services
  • ID&I Nucleus
  • News
  • Privacy Policy

Co-financing

Portuguese laboratory duly authorized by the Portuguese Authorities, the Directorate-General of Health

COPYRIGHT © 2021 BIOSCKIN · POWERED BY ACLSI